REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-17

Reporting Person: COLES N ANTHONY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	M	900	$345.47	Acquired	1802	Direct
2021-08-17	Common Stock	S	900	$650.0	Disposed	902	Direct
2021-08-18	Common Stock	M	5100	$345.47	Acquired	6002	Direct
2021-08-18	Common Stock	S	5100	$650.0	Disposed	902	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-17	Non-Qualified Stock Option (right to buy)	$345.47	M	900	Disposed	2027-01-27	Common Stock (900)	Direct
2021-08-18	Non-Qualified Stock Option (right to buy)	$345.47	M	5100	Disposed	2027-01-27	Common Stock (5100)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.